Xenomics Inc. (XNOM)'s Preliminary Investigation Leads the Company to Believe Sequenom Inc. (SQNM) Willfully Manipulated its Down Syndrome Data in its Presentations
12/17/2009 10:41:20 AM
More...
|
Xenomics Inc. (XNOM) and its Subsidiary TrovaGene, Inc., Announce Italian Patent for NPM1 Testing for AML Patients
12/15/2009 11:51:14 AM
More...
|
Xenomics Inc. (XNOM) Files Suit Against Sequenom Inc. (SQNM) (JOBS) for Fraud
10/29/2009 6:19:04 AM
More...
|
Xenomics Inc. (XNOM) Appoints Bruce A. Huebner as Chief Executive Officer and Board Member
10/6/2009 6:39:45 AM
More...
|
Xenomics Inc. (XNOM) Presents New Diagnostics Platform: Detection of In Vivo Cell Death by Analysis of Cell-Free Tissue-Specific miRNA in Urine or Blood
3/23/2009 9:02:04 AM
More...
|
Xenomics Inc. (XNOM) Provides Update on NPM1 Testing for AML
2/24/2009 10:24:21 AM
More...
|
Editorial Article in the Clinical Chemistry Highlights Significant Progress in Optimization of the Non-Invasive Transrenal DNA Technology Reported by Xenomics Inc. (XNOM)
2/23/2009 10:03:12 AM
More...
|
Xenomics Inc. (XNOM) Offers New Gender Prediction Test to Expectant Mothers
2/17/2009 12:42:30 PM
More...
|
Xenomics Inc. (XNOM) Transrenal Technology Shows Significant Promise in Molecular Diagnostic Applications
2/4/2009 2:35:49 PM
More...
|
Xenomics Inc. (XNOM) Discusses HPV Screening Test Based on Transrenal DNA Technology at 52nd All India Congress of Obstetrics & Gynecology
1/6/2009 11:40:04 AM
More...
|
|